Inventia Recalls 11,460 Chlorthalidone Bottles Nationwide Over Failed Dissolution Tests
Updated
Updated · KOMO News · Jun 21
Inventia Recalls 11,460 Chlorthalidone Bottles Nationwide Over Failed Dissolution Tests
3 articles · Updated · KOMO News · Jun 21
Summary
11,460 bottles of Inventia Healthcare’s chlorthalidone 25 mg tablets were voluntarily recalled across the United States after the blood pressure drug failed dissolution specifications.
The FDA enforcement report said the manufacturing issue means the tablets may not dissolve in the body as intended, potentially affecting treatment for high blood pressure and fluid retention.
The June 5 recall covers 100-count lot RISA24001 and 1,000-count lot RISB24002, both expiring in April 2027 and distributed by Rising Pharma Holdings of New Jersey.
The FDA has not yet classified the recall and no public press release has been issued; patients are advised to check with a pharmacist or healthcare provider before stopping the medication.